Sihuan's 1Q08 Profit Surges 65.8% To RMB53.1Million As Revenue More Than Doubles; Expects FY08 Performance To Exceed That of FY07
Revenue soars 115.4% as Group reaps benefits of increased marketing of cardiocerebral vascular (CV) drugs to top-tier hospitals in China;
Sales of non-CV drugs rise nearly four-fold, buoyed by second quarter of contributions from Shenzhen Sihuan which was acquired in October 2007
Launch of Aogan (or GM-1) and Sodium Ozagrel expected to further consolidate our market positioning in the CV sector in China
Expects to receive more new product approvals to propel future growth in and outside China
No comments:
Post a Comment